Biogen Deal History & Licensing Activity
Biogen is a large biotech headquartered in US. Over the past three years, Biogen has been involved in 42 licensing and acquisition transactions, with a primary focus on Antibodies (20 deals). The company currently has 50 active clinical trials, primarily in Mega Deals.
Deals (12mo)
18
Active Trials
50
Top Modality
Antibodies
Focus Area
Mega Deals
Biogen Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Biogen in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| felzartamab | TJ Biopharma | Antibodies | Unknown | license | Apr 2026 |
| felzartamab | TJ Biopharma | Antibodies | Unknown | license | Apr 2026 |
| felzartamab | TJ | Antibodies | Unknown | license | Apr 2026 |
Biogen Pipeline Focus
Therapeutic areas and modalities where Biogen is most active based on deal history and clinical trial data.
Therapeutic Areas
Biogen Strategic Signals
Key indicators of Biogen's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
Biogen Clinical Pipeline
Biogen has 50 active clinical trials across 6 development phases.
18
Unknown
2
Not Applicable
1
Phase 4
9
Phase 1
8
Phase 2
12
Phase 3
See How Your Asset Matches Biogen's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Mega Deals assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About Biogen Licensing & Deal Activity
Biogen is a large biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 42 deals over the past three years, Biogen ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Biogen include Mega Deals (20 deals and trials), Oncology (16 deals and trials), CNS Disorders (14 deals and trials), and Rare Disease (12 deals and trials). In terms of modality, Biogen has shown particular interest in antibodies, other, oligonucleotides.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Biogen and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Biogen's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.